Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with
lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered
twice-weekly in combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects
with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.